Drug intelligence / Profile preview

CLBS201

Development stage: Phase 1
Lead developer: Lisata Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-renal Artery

Overview

CLBS201 is an investigational autologous CD34+ cell therapy developed by Lisata Therapeutics (formerly Caladrius Biosciences) for the treatment of diabetic kidney disease (DKD) and rapidly progressive chronic kidney disease (CKD). The therapy involves the intra-arterial administration of a patient's own CD34+ hematopoietic stem and progenitor cells directly into the renal arteries. These cells are known for their innate ability to promote the growth of new microvasculature (angiogenesis) and repair damaged tissue. By restoring microvascular density and improving blood flow in the kidneys, CLBS201 aims to attenuate the progression of or potentially reverse renal function decline in patients with type 2 diabetes.

Other names: autologous CD34+ cell therapyautologous CD34+ cells

Beyond the preview

Go deeper on CLBS201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLBS201.

Explore the full profile